JP2005531614A - ワクチン組成物 - Google Patents

ワクチン組成物 Download PDF

Info

Publication number
JP2005531614A
JP2005531614A JP2004512791A JP2004512791A JP2005531614A JP 2005531614 A JP2005531614 A JP 2005531614A JP 2004512791 A JP2004512791 A JP 2004512791A JP 2004512791 A JP2004512791 A JP 2004512791A JP 2005531614 A JP2005531614 A JP 2005531614A
Authority
JP
Japan
Prior art keywords
vesicle
meningococcal
strain
vesicles
bactericidal activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004512791A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005531614A5 (https=
Inventor
バーベラ，モラレス，ラモン，ファウスティノ
デスモン，ピエール，ミッシェル
アルヴァレス，フランシスコ，ヘサス ドミンゲス
プールマン，ジャン
Original Assignee
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
インスティチュート フィンレイ，セントロ デ インヴェスティゲション−プロダクシオン デ スエロス イ ヴァキュナス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラクソスミスクライン バイオロジカルズ ソシエテ アノニム, インスティチュート フィンレイ，セントロ デ インヴェスティゲション−プロダクシオン デ スエロス イ ヴァキュナス filed Critical グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Publication of JP2005531614A publication Critical patent/JP2005531614A/ja
Publication of JP2005531614A5 publication Critical patent/JP2005531614A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2004512791A 2002-06-13 2003-06-10 ワクチン組成物 Pending JP2005531614A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0213622.4A GB0213622D0 (en) 2002-06-13 2002-06-13 Vaccine Corporation
PCT/EP2003/006094 WO2003105890A2 (en) 2002-06-13 2003-06-10 Vaccine composition

Publications (2)

Publication Number Publication Date
JP2005531614A true JP2005531614A (ja) 2005-10-20
JP2005531614A5 JP2005531614A5 (https=) 2006-07-27

Family

ID=9938532

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004512791A Pending JP2005531614A (ja) 2002-06-13 2003-06-10 ワクチン組成物

Country Status (20)

Country Link
US (1) US20060110412A1 (https=)
EP (1) EP1565211A2 (https=)
JP (1) JP2005531614A (https=)
KR (1) KR20050049431A (https=)
CN (1) CN100387298C (https=)
AR (1) AR040204A1 (https=)
AU (1) AU2003236734A1 (https=)
BR (1) BR0311777A (https=)
CA (1) CA2488782A1 (https=)
CL (1) CL2003001192A1 (https=)
CU (1) CU23552A1 (https=)
GB (1) GB0213622D0 (https=)
MX (1) MXPA04012568A (https=)
NO (1) NO20050132L (https=)
NZ (1) NZ560766A (https=)
PE (1) PE20040562A1 (https=)
RU (1) RU2005100509A (https=)
UY (1) UY27843A1 (https=)
WO (1) WO2003105890A2 (https=)
ZA (1) ZA200409547B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011511275A (ja) * 2008-02-01 2011-04-07 サノフィ パストゥール リミテッド 診断的アッセイ
JP2013507354A (ja) * 2009-10-08 2013-03-04 イオン メディックス インコーポレイテッド 室内空気由来細胞外ベシクルを含む組成物及びその用途
JP2016104776A (ja) * 2009-12-22 2016-06-09 サノフィ パストゥール リミテッドＳａｎｏｆｉ Ｐａｓｔｅｕｒ Ｌｉｍｉｔｅｄ 免疫原性組成物

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2519440T3 (es) 2000-07-27 2014-11-07 Children's Hospital & Research Center At Oakland Vacunas para la protección de amplio espectro contra enfermedades causadas por Neisseria meningitidis
GB2414667A (en) * 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
WO2006081259A2 (en) 2005-01-27 2006-08-03 Children's Hospital & Research Center At Oakland Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
KR101515078B1 (ko) * 2005-12-22 2015-04-24 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
JP5814507B2 (ja) 2006-09-07 2015-11-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
BR122016015627A2 (pt) 2007-10-19 2018-10-30 Novartis Ag kit, composição antigênica liofilizada e método para preparação de uma composição imunogênica
JP2011503104A (ja) 2007-11-09 2011-01-27 カリフォルニア インスティテュート オブ テクノロジー 免疫調節化合物ならびに関連組成物および方法
CN102015651B (zh) 2008-03-03 2014-12-31 Irm责任有限公司 作为tlr活性调节剂的化合物和组合物
WO2010070453A2 (en) 2008-12-17 2010-06-24 Novartis Ag Meningococcal vaccines including hemoglobin receptor
JP5867952B2 (ja) 2009-06-10 2016-02-24 ノバルティス アーゲー ベンゾナフチリジン含有ワクチン
EP2470205A1 (en) 2009-08-27 2012-07-04 Novartis AG Adjuvant comprising aluminium, oligonucleotide and polycation
WO2011027222A2 (en) 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
BR112012014624A8 (pt) 2009-12-15 2017-12-26 Novartis Ag suspensão homogênea de compostos de imunopotenciação e usos dos destes
AU2011288203A1 (en) 2010-03-18 2012-08-23 Novartis Ag Adjuvanted vaccines for serogroup B meningococcus
EA031379B1 (ru) 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
JP6027961B2 (ja) 2010-04-07 2016-11-16 シェン, ユエSHEN, Yue 粘膜へ化合物を送るための媒体、それに関連する組成物、方法、及びシステム
US9259462B2 (en) * 2010-09-10 2016-02-16 Glaxosmithkline Biologicals Sa Developments in meningococcal outer membrane vesicles
US20150147356A1 (en) 2011-05-12 2015-05-28 Alan Kimura Antipyretics to enhance tolerability of vesicle-based vaccines
US9539281B2 (en) 2011-07-12 2017-01-10 The Brigham And Women's Hospital, Inc. Lipid-containing PSA compositions, methods of isolation and methods of use thereof
EP3299467B1 (en) 2012-02-02 2021-08-11 GlaxoSmithKline Biologicals SA Promoters for increased protein expression in meningococcus
US10598666B2 (en) 2012-03-08 2020-03-24 Glaxosmithkline Biologicals Sa In vitro potency assay for protein-based meningococcal vaccines
AU2013276083B2 (en) 2012-06-14 2018-04-05 Institut Pasteur Vaccines for serogroup X meningococcus
JP6324961B2 (ja) 2012-09-06 2018-05-16 ノバルティス アーゲー 血清群ｂ髄膜炎菌とｄ／ｔ／ｐとの組み合わせワクチン
WO2016201342A1 (en) 2015-06-10 2016-12-15 California Institute Of Technology Sepsis treatment and related compositions methods and systems
JP6918365B2 (ja) 2015-08-19 2021-08-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 脂質化ｐｓａ組成物および方法
US11491181B2 (en) 2016-07-15 2022-11-08 President And Fellows Of Harvard College Glycolipid compositions and methods of use
US12109259B2 (en) 2016-09-02 2024-10-08 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
MX2023004729A (es) * 2020-10-23 2023-06-29 Omvax Inc Composiciones y metodos de vacunacion contra neisseria gonorrhoeae.
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2297072A1 (en) * 1997-07-17 1999-01-28 Baxter Healthcare S.A. Immunogenic conjugates comprising a group b meningococcal porin and an h. influenzae polysaccharide
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
ES2519440T3 (es) * 2000-07-27 2014-11-07 Children's Hospital & Research Center At Oakland Vacunas para la protección de amplio espectro contra enfermedades causadas por Neisseria meningitidis

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011511275A (ja) * 2008-02-01 2011-04-07 サノフィ パストゥール リミテッド 診断的アッセイ
JP2013507354A (ja) * 2009-10-08 2013-03-04 イオン メディックス インコーポレイテッド 室内空気由来細胞外ベシクルを含む組成物及びその用途
JP2016104776A (ja) * 2009-12-22 2016-06-09 サノフィ パストゥール リミテッドＳａｎｏｆｉ Ｐａｓｔｅｕｒ Ｌｉｍｉｔｅｄ 免疫原性組成物

Also Published As

Publication number Publication date
NZ560766A (en) 2009-09-25
KR20050049431A (ko) 2005-05-25
BR0311777A (pt) 2005-03-29
GB0213622D0 (en) 2002-07-24
UY27843A1 (es) 2003-12-31
NO20050132L (no) 2005-02-11
CN100387298C (zh) 2008-05-14
AU2003236734A1 (en) 2003-12-31
PE20040562A1 (es) 2004-10-19
MXPA04012568A (es) 2005-09-21
US20060110412A1 (en) 2006-05-25
AR040204A1 (es) 2005-03-16
EP1565211A2 (en) 2005-08-24
CU23552A1 (es) 2010-07-20
CL2003001192A1 (es) 2005-01-07
CA2488782A1 (en) 2003-12-24
CN1668329A (zh) 2005-09-14
WO2003105890A2 (en) 2003-12-24
NO20050132D0 (no) 2005-01-11
ZA200409547B (en) 2006-07-26
RU2005100509A (ru) 2006-06-10
WO2003105890A3 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
CN100387298C (zh) 疫苗组合物
TWI360424B (en) Vaccine
JP5275983B2 (ja) ワクチン
US20050244436A1 (en) Combination Neisserial compositions
US20170209562A1 (en) Immunogenic composition
Pinto et al. An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups
EP1572729B1 (en) Mutant frpb protein and refolding method
EP1532168A2 (en) Method for refolding neisserial nspa protein
RU2359696C2 (ru) Вакцинная композиция, содержащая трансферрин-связывающий белок и hsf из грамотрицательных бактерий
AU2016228231A1 (en) Combination Neisserial compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060606

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091224

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101102